Product
SCY-078
Aliases
Ibrexafungerp
Name
BREXAFEMME
INN Name
ibrexafungerp
FDA Approved
Yes
4 clinical trials
1 organization
5 indications
1 document
Indication
Invasive Pulmonary AspergillosisIndication
CandidiasisIndication
InvasiveIndication
CandidemiaIndication
MycosisClinical trial
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary AspergillosisStatus: Completed, Estimated PCD: 2023-03-27
Clinical trial
Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida AurisStatus: Completed, Estimated PCD: 2023-04-14
Clinical trial
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)Status: , Estimated PCD: 2024-06-01
Clinical trial
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic AdultsStatus: Completed, Estimated PCD: 2016-06-01
Document
DailyMed Label: BREXAFEMMEOrganization
SCYNEXIS, INC.